PGNX Progenics Pharmaceuticals Inc.

6.96
+0.00  (0%)
Previous Close 6.96
Open 6.93
Price To book 6.57
Market Cap 489078142
Shares 70,269,848
Volume 573,955
Short Ratio 5.98
Av. Daily Volume 1,136,071

SEC filingsSee all SEC filings

  1. 8-K/A [Amend] - Current report 171091291
  2. 8-K - Current report 171064028
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 171016597
  4. 8-K - Current report 171016468
  5. 8-K - Current report 17969952

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2/3 initiation announced December 7, 2016.
PyL
Prostate cancer
Phase 2b primary endpoint met - March 2017. Noted August 31, 2017 that NDA filing has been delayed until manufacturing site is FDA inspection-ready.
Azedra
Pheochromocytoma
Phase 3 interim analysis completed December 22, 2016 by Data Monitoring Committee (DMC). Trial to continue.
1404
Help visualize prostate cancer by targeting prostate specific membrane antigen (PSMA)
Approved July 19 2016.
Oral RELISTOR
Chronic pain
Approved September 29, 2014.
Subcutaneous RELISTOR
Chronic pain
Abstract released at American Society of Clinical Oncology's 2014 Genitourinary Cancers Symposium Meeting in San Francisco in January 28 2014.
PSMA ADC
Cancer - metastatic castrate resistant prostate cancer (mCRPC).

Latest News

  1. Progenics Pharmaceuticals to Present at the Cantor Fitzgerald 2017 Global Healthcare Conference
  2. What's Behind Progenics Pharmaceuticals, Inc.'s Bump Today?
  3. 3 Biotech Stocks I'd Buy Right Now
  4. ETFs with exposure to Progenics Pharmaceuticals, Inc. : September 14, 2017
  5. Progenics Pharmaceuticals, Inc. :PGNX-US: Earnings Analysis: Q2, 2017 By the Numbers : September 13, 2017
  6. Progenics Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : PGNX-US : September 12, 2017
  7. Progenics Pharmaceuticals, Inc. – Value Analysis (NASDAQ:PGNX) : September 2, 2017
  8. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Progenics Pharmaceuticals Inc. - PGNX
  9. Progenics Pharmaceuticals Presents Data from AZEDRA® Pivotal Phase 2b Study at the 5th International Symposium on Pheochromocytoma and Paraganglioma
  10. Progenics Pharmaceuticals Provides Update on Timing of NDA Submission for AZEDRA®
  11. Progenics Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : PGNX-US : August 30, 2017
  12. Progenics Pharmaceuticals, Inc.: Gathering momentum, can it sustain its performance?
  13. 3 Beaten-Up Biotech Stocks: Are They Bargains?
  14. Edited Transcript of PGNX earnings conference call or presentation 9-Aug-17 12:30pm GMT
  15. Progenics reports 2Q loss
  16. Here's Why Progenics Pharmaceuticals, Inc. Lost Ground Today
  17. Progenics Pharmaceuticals Announces Second Quarter 2017 Financial Results and Business Update
  18. Investor Network: Progenics Pharmaceuticals, Inc. to Host Earnings Call
  19. ETFs with exposure to Progenics Pharmaceuticals, Inc. : August 4, 2017
  20. Progenics Pharmaceuticals Sets Second Quarter 2017 Financial Results Call for August 9